^
    Apply
    A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) (NCT03964233)
    Phase 1
    Boehringer Ingelheim
    Active, not recruiting
    Last update posted :
    06/11/2024
    Initiation :
    06/11/2019
    Primary completion :
    09/03/2024
    Completion :
    05/30/2026
    TP53 • MDM2
    |
    TP53 mutation • TP53 wild-type • TP53 amplification
    |
    brigimadlin (BI 907828) • ezabenlimab (BI 754091) • miptenalimab (BI 754111)
    This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer (NCT03433898)
    Phase 1
    Boehringer Ingelheim
    Completed
    Last update posted :
    07/28/2023
    Initiation :
    02/23/2018
    Primary completion :
    07/20/2023
    Completion :
    07/20/2023
    EGFR • ALK
    |
    PD-L1 expression • ALK rearrangement
    |
    ezabenlimab (BI 754091) • miptenalimab (BI 754111)
    This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. (NCT03156114)
    Phase 1
    Boehringer Ingelheim
    Completed
    Last update posted :
    06/29/2023
    Initiation :
    06/13/2017
    Primary completion :
    03/09/2023
    Completion :
    06/06/2023
    EGFR • ALK • TMB • MSI
    |
    PD-L1 expression • TMB-H • MSI-H/dMMR • PD-L1 overexpression • EGFR wild-type • ALK wild-type
    |
    ezabenlimab (BI 754091) • miptenalimab (BI 754111)